263 related articles for article (PubMed ID: 32340119)
1. Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses.
Farrera-Sal M; Fillat C; Alemany R
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32340119
[TBL] [Abstract][Full Text] [Related]
2. Arming Oncolytic Adenoviruses: Effect of Insertion Site and Splice Acceptor on Transgene Expression and Viral Fitness.
Farrera-Sal M; de Sostoa J; Nuñez-Manchón E; Moreno R; Fillat C; Bazan-Peregrino M; Alemany R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708234
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.
Robinson M; Ge Y; Ko D; Yendluri S; Laflamme G; Hawkins L; Jooss K
Cancer Gene Ther; 2008 Jan; 15(1):9-17. PubMed ID: 17853920
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Adenovirus: Prospects for Cancer Immunotherapy.
Zhao Y; Liu Z; Li L; Wu J; Zhang H; Zhang H; Lei T; Xu B
Front Microbiol; 2021; 12():707290. PubMed ID: 34367111
[TBL] [Abstract][Full Text] [Related]
5. The genome position of a therapeutic transgene strongly influences the level of expression in an armed oncolytic human adenovirus vector.
Clarkin RG; Del Papa J; Poulin KL; Parks RJ
Virology; 2021 Sep; 561():87-97. PubMed ID: 34171766
[TBL] [Abstract][Full Text] [Related]
6. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
[TBL] [Abstract][Full Text] [Related]
7. Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses.
Núñez-Manchón E; Farrera-Sal M; Otero-Mateo M; Castellano G; Moreno R; Medel D; Alemany R; Villanueva E; Fillat C
NAR Cancer; 2021 Jun; 3(2):zcab015. PubMed ID: 34316705
[TBL] [Abstract][Full Text] [Related]
8. Current development in adenoviral vectors for cancer immunotherapy.
Biegert GWG; Rosewell Shaw A; Suzuki M
Mol Ther Oncolytics; 2021 Dec; 23():571-581. PubMed ID: 34938857
[TBL] [Abstract][Full Text] [Related]
9. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site.
Carette JE; Graat HC; Schagen FH; Abou El Hassan MA; Gerritsen WR; van Beusechem VW
J Gene Med; 2005 Aug; 7(8):1053-62. PubMed ID: 15756711
[TBL] [Abstract][Full Text] [Related]
10. A three-plasmid system for construction of armed oncolytic adenovirus.
Liu HY; Han BJ; Zhong YX; Lu ZZ
J Virol Methods; 2009 Dec; 162(1-2):8-13. PubMed ID: 19646479
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Adenovirus in Cancer Immunotherapy.
Peter M; Kühnel F
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33202717
[TBL] [Abstract][Full Text] [Related]
12. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo.
Rivera AA; Wang M; Suzuki K; Uil TG; Krasnykh V; Curiel DT; Nettelbeck DM
Virology; 2004 Mar; 320(1):121-34. PubMed ID: 15003868
[TBL] [Abstract][Full Text] [Related]
13. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.
Bortolanza S; Bunuales M; Alzuguren P; Lamas O; Aldabe R; Prieto J; Hernandez-Alcoceba R
Cancer Gene Ther; 2009 Sep; 16(9):703-12. PubMed ID: 19229289
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges.
Chaurasiya S; Fong Y; Warner SG
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32604787
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.
Lamfers ML; Fulci G; Gianni D; Tang Y; Kurozumi K; Kaur B; Moeniralm S; Saeki Y; Carette JE; Weissleder R; Vandertop WP; van Beusechem VW; Dirven CM; Chiocca EA
Mol Ther; 2006 Dec; 14(6):779-88. PubMed ID: 16996314
[TBL] [Abstract][Full Text] [Related]
16. Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli.
Hoffmann D; Wildner O
BMC Biotechnol; 2006 Aug; 6():36. PubMed ID: 16887042
[TBL] [Abstract][Full Text] [Related]
17. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.
Ino Y; Saeki Y; Fukuhara H; Todo T
Clin Cancer Res; 2006 Jan; 12(2):643-52. PubMed ID: 16428511
[TBL] [Abstract][Full Text] [Related]
18. Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives.
McKenna MK; Rosewell-Shaw A; Suzuki M
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32155969
[TBL] [Abstract][Full Text] [Related]
19. Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs.
Heiniö C; Sorsa S; Siurala M; Grönberg-Vähä-Koskela S; Havunen R; Haavisto E; Koski A; Hemminki O; Zafar S; Cervera-Carrascon V; Munaro E; Kanerva A; Hemminki A
Hum Gene Ther; 2019 Jun; 30(6):740-752. PubMed ID: 30672366
[TBL] [Abstract][Full Text] [Related]
20. Development of a Novel Oncolytic Adenovirus Expressing a Short-hairpin RNA Against Cullin 4A.
Wakabayashi K; Sakurai F; Ono R; Fujiwara T; Mizuguchi H
Anticancer Res; 2020 Jan; 40(1):161-168. PubMed ID: 31892564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
